These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2232168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
    Yamaguchi A, Kurosaka Y, Ohta N, Kamata T, Ishida T, Nishimura G, Katoh M, Kosaka T, Yonemura Y, Miyazaki I.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery].
    Sakurai Y, Kodaira S, Teramoto T, Sugano K, Abe O, Ohtake H, Iri H.
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914
    [Abstract] [Full Text] [Related]

  • 6. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
    Anzai K, Kurihara M, Izumi T.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul 20; 25(7):1437-47. PubMed ID: 2212836
    [Abstract] [Full Text] [Related]

  • 7. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
    Suzuki S, Nihei M, Nomizu T, Watanabe T, Kimijima I, Tsuchiya A, Abe R.
    Nihon Gan Chiryo Gakkai Shi; 1990 May 20; 25(5):1019-26. PubMed ID: 2202768
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K, Schmid H, Hanke J, Kaufmann M, Müller A.
    Geburtshilfe Frauenheilkd; 1988 May 20; 48(5):309-12. PubMed ID: 3165077
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K, Watanabe K, Ishida T, Sakurai M, Amano R, Hagiwara H, Hara Y, Hanzawa T, Itsubo K.
    Gan To Kagaku Ryoho; 1986 Oct 20; 13(11):3145-9. PubMed ID: 3465273
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M, Tikanoja S, Brown J.
    Anticancer Res; 1990 Oct 20; 10(4):959-62. PubMed ID: 2382995
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
    Yoshimoto M.
    Gan To Kagaku Ryoho; 1990 Nov 20; 17(11):2277-83. PubMed ID: 2241194
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.